Oncternal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 09, 2023 at 04:31 pm EST
Oncternal Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 9.86 million compared to USD 11.13 million a year ago. Basic loss per share from continuing operations was USD 3.4 compared to USD 4.2 a year ago.
For the nine months, net loss was USD 30.32 million compared to USD 32.77 million a year ago. Basic loss per share from continuing operations was USD 10.4 compared to USD 12.8 a year ago.